Cardiac Myosin Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the cardiac myosin inhibitor [epc] class. 8 active patents protecting 1 drugs. First major cliff: 2034. Daily refresh.

1
Drugs in class
8
Active US patents
44/100
Avg vulnerability
$600M
Annual revenue covered

Originators

Bristol-Myers Squibb 8 patents

Cliff calendar — next 15 years

4
34
4
36

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Camzyos
MAVACAMTEN
 Bristol-Myers Squibb 8 44 $600M 2034-06-19

Most attackable patents

Patent Drug Type Vuln Expiry
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28

Strongest defences

Patent Drug Type Vuln Expiry
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
RE50050 Camzyos composition of matter 17 2036-04-28
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19
9585883 Camzyos method of use 70 2034-06-19

Related